Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22552299 | 1.00 | DHODH (1.00) | DHODH | |
| SCHEMBL22552219 | 1.00 | DHODH (1.00) | DHODH | |
| SCHEMBL29404093 | 1.00 | DHODH (1.00) | DHODH | |
| SCHEMBL22552202 | 0.91 | DHODH (1.00) | DHODH | |
| SCHEMBL22552173 | 0.91 | DHODH (1.00) | DHODH | |
| SCHEMBL29401620 | 0.91 | DHODH (1.00) | DHODH | |
| SCHEMBL29401439 | 0.91 | DHODH (1.00) | DHODH | |
| SCHEMBL22552475 | 0.81 | DHODH (0.78) | DHODH | |
| SCHEMBL22552494 | 0.81 | DHODH (0.78) | DHODH | |
| SCHEMBL22552338 | 0.81 | DHODH (0.78) | DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114174278-B | Dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2024-08-23 | — | — | CN | claimed |
| EP-4337215-A1 | COMBINATION THERAPIES | JANSSEN Pharmaceutica NV (BE) | 2024-03-20 | — | — | EP | claimed |
| WO-2022237719-A1 | COMBINATION THERAPIES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | WO | claimed |
| WO-2022074534-A1 | COMBINATIONS OF DIHYDROOROTATE DEHYDROGENASE INHIBITORS AND HYPOMETHYLATING AGENTS | JANSSEN BIOTECH, INC. (US) | 2022-04-14 | — | — | WO | claimed |
| CN-114174278-A | Dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2022-03-11 | — | — | CN | claimed |
| EP-3956320-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Janssen Biotech, Inc. (US) | 2022-02-23 | — | — | EP | claimed |
| EP-4626427-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND A BCL-2 INHIBITOR | Janssen Pharmaceutica NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4626426-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND AT LEAST ONE OTHER THERAPEUTIC AGENT | JANSSEN Pharmaceutica NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| CN-118845786-A | Combination therapy | 詹森药业有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118845787-A | Combination therapy | 詹森药业有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-114174278-B | Dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2024-08-23 | — | — | CN | disclosed |
| WO-2024114666-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND A BCL-2 INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024114664-A1 | COMBINATIONS COMPRISING A MENIN-MLL INHIBITOR AND AT LEAST ONE OTHER THERAPEUTIC AGENT | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| CN-117460513-A | Combination therapy | 詹森药业有限公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-3956320-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2023-11-29 | — | — | EP | disclosed |
| WO-2022237719-A1 | COMBINATION THERAPIES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022237720-A1 | COMBINATION THERAPIES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022074534-A1 | COMBINATIONS OF DIHYDROOROTATE DEHYDROGENASE INHIBITORS AND HYPOMETHYLATING AGENTS | JANSSEN BIOTECH, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-114174278-A | Dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3956320-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Janssen Biotech, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |